omeprazole has been researched along with Obesity, Morbid in 6 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Obesity, Morbid: The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Healthy patients with obesity (body mass index >35) were included and assessed for omeprazole PKs before and after RYGB (1 and 6 months)." | 9.51 | Effect of Obesity and Roux-En-Y Gastric Surgery on Omeprazole Pharmacokinetics. ( Bandrés, F; Castrillón, EV; Chicharro, LM; López-Picado, A; Moreno Lopera, C; Paterna, ABR; Portolés-Pérez, A; Rubio, MA; Sánchez Pernaute, A; Torres García, AJ, 2022) |
| " Healthy patients with obesity (body mass index >35) were included and assessed for omeprazole PKs before and after RYGB (1 and 6 months)." | 5.51 | Effect of Obesity and Roux-En-Y Gastric Surgery on Omeprazole Pharmacokinetics. ( Bandrés, F; Castrillón, EV; Chicharro, LM; López-Picado, A; Moreno Lopera, C; Paterna, ABR; Portolés-Pérez, A; Rubio, MA; Sánchez Pernaute, A; Torres García, AJ, 2022) |
| "For SA, Tmax significantly decreased after RYGB, while both Cmax and AUC0-24 significantly increased." | 2.82 | The Effect of Roux-en-Y Gastric Bypass Surgery in Morbidly Obese Patients on Pharmacokinetics of (Acetyl)Salicylic Acid and Omeprazole: the ERY-PAO Study. ( Mitrov-Winkelmolen, L; Overdiek, HWPM; Swank, DJ; Touw, DJ; van Buul-Gast, MW; van Schaik, RHN, 2016) |
| " For the duration of 4 months, weight, body mass index, and the occurrence of adverse events was documented." | 1.48 | The safety and efficacy of the procedureless intragastric balloon. ( Al Haddad, E; Al Kendari, M; Al-Subaie, S; Almulla, A; Alsabah, S; Ekrouf, S, 2018) |
| "In the absence of clinical studies, the ability to project the direction and the magnitude of changes in bioavailability of drug therapy, using evidence-based mechanistic pharmacokinetic in silico models would be of significant value in guiding prescribers to make the necessary adjustments to dosage regimens for an increasing population of patients who are undergoing bariatric surgery." | 1.38 | A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution. ( Ammori, BJ; Ashcroft, DM; Darwich, AS; Jamei, M; Pade, D; Rostami-Hodjegan, A, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Portolés-Pérez, A | 1 |
| Paterna, ABR | 1 |
| Sánchez Pernaute, A | 1 |
| Torres García, AJ | 1 |
| Moreno Lopera, C | 1 |
| Chicharro, LM | 1 |
| Bandrés, F | 1 |
| López-Picado, A | 1 |
| Rubio, MA | 1 |
| Castrillón, EV | 1 |
| Collares-Pelizaro, RVA | 1 |
| Santos, JS | 1 |
| Nonino, CB | 1 |
| dos Reis Dias, LA | 1 |
| Gaitani, CM | 1 |
| Salgado, W | 1 |
| Alsabah, S | 1 |
| Al Haddad, E | 1 |
| Ekrouf, S | 1 |
| Almulla, A | 1 |
| Al-Subaie, S | 1 |
| Al Kendari, M | 1 |
| Mitrov-Winkelmolen, L | 1 |
| van Buul-Gast, MW | 1 |
| Swank, DJ | 1 |
| Overdiek, HWPM | 1 |
| van Schaik, RHN | 1 |
| Touw, DJ | 1 |
| Darwich, AS | 1 |
| Pade, D | 1 |
| Ammori, BJ | 1 |
| Jamei, M | 1 |
| Ashcroft, DM | 1 |
| Rostami-Hodjegan, A | 1 |
| Ardengh, JC | 1 |
| Domene, CE | 1 |
| Valiati, LH | 1 |
| Morrell, AC | 1 |
3 trials available for omeprazole and Obesity, Morbid
| Article | Year |
|---|---|
Effect of Obesity and Roux-En-Y Gastric Surgery on Omeprazole Pharmacokinetics.
Topics: Body Mass Index; Body Weight; Female; Gastric Bypass; Humans; Male; Obesity; Obesity, Morbid; Omepra | 2022 |
Omeprazole Absorption and Fasting Gastrinemia After Roux-en-Y Gastric Bypass.
Topics: Adult; Anastomosis, Roux-en-Y; Fasting; Female; Gastric Bypass; Gastrins; Humans; Male; Middle Aged; | 2017 |
The Effect of Roux-en-Y Gastric Bypass Surgery in Morbidly Obese Patients on Pharmacokinetics of (Acetyl)Salicylic Acid and Omeprazole: the ERY-PAO Study.
Topics: Administration, Oral; Anti-Ulcer Agents; Area Under Curve; Aspirin; Female; Gastric Bypass; Humans; | 2016 |
3 other studies available for omeprazole and Obesity, Morbid
| Article | Year |
|---|---|
The safety and efficacy of the procedureless intragastric balloon.
Topics: Adult; Antiemetics; Body Mass Index; Drug Therapy, Combination; Female; Gastric Balloon; Humans; Kuw | 2018 |
A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution.
Topics: Administration, Oral; Bariatric Surgery; Biological Availability; Chemistry, Pharmaceutical; Ciprofl | 2012 |
Conservative management of esophageal perforation following obesity surgery.
Topics: Anti-Bacterial Agents; Ceftriaxone; Enteral Nutrition; Enzyme Inhibitors; Esophageal Perforation; Fe | 2006 |